CeriBell, Inc. (CBLL)
Nasdaq · Healthcare · Medical Devices
$24.86+4.94%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $954M
- 52-week range
- $10.85 – $25.63
- 52-week change
- +88.46%
- EPS (trailing)
- −$1.76
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $89.1M (+36.09%)
- Net income
- −$53.4M
- Operating margin
- −65.6%
- Diluted EPS
- −$1.46
- Free cash flow
- −$41.6M
From the company’s annual report on SEC EDGAR.
About CeriBell, Inc.
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Headquarters: Sunnyvale, United States · 327 employees · ceribell.com